https://tbdpharmatech.comTBD Pharmatech – Contract Development and ManufacturingTBD Pharmatech specialises in Active Pharmaceutical Ingredients, advanced intermediates, and the development and production of fine chemicals
Name
ToxInvent OÜ
Registry code
12805625
VAT number
EE101777177
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
25.02.2015 (9)
Financial year
01.01-31.12
Capital
4 223.00 €
Activity
20591 - Manufacture of other chemical products n.e.c.
804 543 €
42 585 €
5%
2 626 €
(estimate is approximate)
655 766 €
1
Submitted
No tax arrears
6%
6%
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| OÜ KALTEC 10804159 | 100% - 4 223.00 EUR | - | - | Founder |
| Andrus Tasa 10.01.1966 (58) | - | Board member | Direct ownership | |
| osaühing ÖKOTEH 10085210 | - | - | - | Founder |
| osaühing TorroSen 10563572 | - | - | - | Founder |
| Olga Tšubrik 25.11.1979 (44) | - | - | - | Founder |
| Uno Mäeorg 22.08.1950 (74) | - | - | - | Founder |
| 2019 07.04.2020 | 2020 08.02.2021 | 2021 15.03.2022 | 2022 07.03.2023 | 2023 25.01.2024 | |
|---|---|---|---|---|---|
| Total Revenue | 566 855 € | 549 444 € | 631 941 € | 711 672 € | 804 543 € |
| Net profit (loss) for the period | 126 865 € | 125 357 € | -142 493 € | 73 383 € | 42 585 € |
| Profit Margin | 22% | 23% | -23% | 10% | 5% |
| Current Assets | 280 486 € | 224 026 € | 219 046 € | 129 717 € | 334 325 € |
| Fixed Assets | 292 929 € | 592 254 € | 324 968 € | 487 247 € | 330 626 € |
| Total Assets | 573 415 € | 816 280 € | 544 014 € | 616 964 € | 664 951 € |
| Current Liabilities | 16 481 € | 133 989 € | 4 216 € | 3 783 € | 9 185 € |
| Non Current Liabilities | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - |
| Share Capital | - | - | - | - | - |
| Equity | 556 934 € | 682 291 € | 539 798 € | 613 181 € | 655 766 € |
| Employees | 2 | 2 | 1 | 1 | 1 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 157 461.52 € | - | 5 668.91 € | 1 |
| 2023 Q4 | 135 397.38 € | - | 3 800.52 € | 1 |
| 2023 Q3 | 284 413.8 € | 3 634.92 € | 3 800.52 € | 1 |
| 2023 Q2 | 238 434.44 € | 3 476.88 € | 3 635.28 € | 1 |
| 2023 Q1 | 172 882.69 € | - | 3 304.8 € | 1 |
| 2022 Q4 | 153 407.15 € | - | 3 363.77 € | 1 |
| 2022 Q3 | 174 571.84 € | 3 160.8 € | 3 304.8 € | 1 |
| 2022 Q2 | 246 933.67 € | - | 3 304.8 € | 1 |
| 2022 Q1 | 152 113.18 € | 3 160.8 € | 3 304.8 € | 1 |
| 2021 Q4 | 153 909.26 € | - | 3 294.82 € | 1 |
| 2021 Q3 | 176 112.06 € | - | 6 753.19 € | 1 |
| 2021 Q2 | 219 452.93 € | - | 3 304.8 € | 2 |
| 2021 Q1 | 170 260.3 € | - | 7 953.09 € | 1 |
| 2020 Q4 | 58 919.17 € | - | 6 705.6 € | 3 |
| 2020 Q3 | 112 699.86 € | 6 297.6 € | 6 705.6 € | 3 |
| 2020 Q2 | 231 633.73 € | - | 6 705.6 € | 3 |
| 2020 Q1 | 81 905.46 € | 6 297.6 € | 6 705.6 € | 3 |
